SkinBioTherapeutics (LON:SBTX) Hits New 52-Week Low – What’s Next?

Shares of SkinBioTherapeutics plc (LON:SBTX) reached a new 52-week low during trading on Monday. The stock traded as low as GBX 4.50 and last traded at GBX 4.71, with a volume of 190,895 shares changing hands. The stock had previously closed at GBX 5.

SkinBioTherapeutics Stock Down 5.7%

The stock has a market capitalization of £12.22 million, a price-to-earnings ratio of -29.47 and a beta of 0.10. The business has a fifty day moving average of GBX 6.75 and a 200 day moving average of GBX 9.90. The company has a debt-to-equity ratio of 11.77, a current ratio of 6.14 and a quick ratio of 10.01.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.